TABLE 3.
PRRs for patients with P. vivax infection described for the various treatment groups
| Group | PRR24a | No. of patients for PRR24 | PRR48a | No. of patients for PRR48 | PRR96a | No. of patients for PRR96 |
|---|---|---|---|---|---|---|
| CPb | 12 (2–509) | 27 | 90 (2–2,747) | 21 | 882 (457–1,306) | 2 |
| Chloroquine | 36 (1–1,184) | 30 | 438 (33–2,575) | 23 | 972 | 1 |
| Primaquine | 2 (<1–692) | 28 | 9 (<1–692) | 27 | 315 (9–2,579) | 13 |
| Quinine | 4 (1–54) | 22 | 97 (3.5–561) | 22 | 1,498 (178–3,266) | 8 |
| Mefloquine | 12 (2–332) | 20 | 449 (18–3,182) | 19 | 1,572 (754–1,968) | 4 |
| Halofantrine | 7 (1–276) | 23 | 201 (<1–2,079) | 20 | 1,427 (521–2,020) | 4 |
| Artesunate | 844 (110–2,613) | 17 | 1,507 (146–2,531) | 5 | 0 | |
| Artemether | 508 (57–3,869) | 20 | 1,720 (339–2,311) | 8 | 0 | |
| PS | 2 (<1–381) | 12 | 15 (2–1,330) | 11 | 139 (13–2,160) | 10 |
| Total | 12 (<1–3,869) | 199 | 112 (<1–3,182) | 156 | 641 (9–3,266) | 42 |
a
Data are medians (ranges).
b
CP, chloroquine-primaquine.